Hasil Pencarian  ::  Simpan CSV :: Kembali

"Tujuan Penyesuaian dosis dan pemilihan jenis obat penting dilakukan dalam keadaan gangguan fungsi ginjal. Penelitian observasional ini bertujuan untuk mengetahui ketepatan penyesuaian dosis dan ketepatan pemilihan obat pada pasien di ruang rawat inap Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia/Rumah Sakit Dr. Cipto Mangunkusumo, Jakarta.Metode Pasien usia 18 tahun atau lebih dengan bersihan kreatinin <60 mL/menit berdasarkan rumus Cockroft-Gault diikutkan dalam penelitian ini. Obat yang dinilai adalah obat yang ekskresinya terutama melalui ginjal dan obat-obat yang bersifat nefrotoksik. Ketepatan pemilihan dinilai berdasarkan ada/tidaknya kontraindikasi dan interaksi potensial antar obat yang digunakan, sedangkan ketepatan penyesuaian dosis didasarkan pada berbagai literature buku teks dan brosur obat. Data dikumpulkan antara bulan May sampai July 2007.Hasil Dari 43 pasien yang memenuhi kriteria inklusi, didapatkan pemakaian obat sebanyak 385 jenis, 164 jenis di antaranya mempunyai jalur ekskresi utama di ginjal dan/atau bersifat nefrotoksik. Dari 164 jenis obat tersebut, penyesuaian dosis dilakukan dengan tepat pada 142 jenis obat (86.5%), sedangkan penyesuaian yang tidak tepat terdapat pada 22 jenis obat (13.5%). Terdapat 1 pemakaian obat yang merupakan kontraindikasi, dan 15.1% dinilai potensial berinteraksi.Kesimpulan Penyesuaian dosis dan pemilihan obat pada pasien gangguan fungsi ginjal di ruang rawat inap Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia/Rumah Sakit Dr. Cipto Mangunkusumo telah dilakukan dengan baik.

---

Aim Dose adjusment and drug selection is important in patient with renal dysfuction.This study was aimed to assess the accuracy of dose adjustment and drug selection for renal dysfunction patient at the Internal Medicine Ward FMUI/Dr. Cipto Mangunkusumo Hospital, Jakarta.

Methods Patients ≥ 18 years old with estimated creatinine clearance < 60 mL/minute based on Cockroft-Gault formula were included in this study. The drugs assessed were those excreted by the kidney or having nephrotoxic effect. The appropriateness of drug selection is assessed based on the preserce or not contraindication or potential of drug-drug interaction. The accuracy of dose adjustment were assessed based on information available in various textbooks, literatures, and drug brochures. Data were collected between May to July 2007.

Results Data obtained from 43 patients met the inclusion criterias demonstrated that 164 out of 385 drug prescriptions were mainly eliminated by the kidney or have nephrotoxic characteristic. Out of 164 drug prescriptions, 142 (86.5%) were appropriately adjusted, while the other 22 (13.5%) were inappropriately adjusted for the dose. There was only one contraindication for the usage of the drug and 15.1% potentially drug interaction.

Conclusion Dose adjustment and drug selections in patients with renal dysfunction at the Internal Medicine Ward FMUI/Dr. Cipto Mangunkusumo Hospital are conducted appropriately."

"scleroderma is an autoimmune disease characterized by organ fibrosis, resistant to standard treatment. It is suspected the addition of Physalis angulata Linn. (Ciplukan) extract as adjuvant therapy can improve the scleroderma skin fibrosis. The aim at this study is to evaluate the effect of ciplukan extract as adjuvant on scleroderma skin fibrosis in standard therapy, based on modified Rodnan skin scale (MRSS), inflammatory biomarkers, immunology and serum fibrosis. Methods: double-blind, randomized clinical trial was performed in scleroderma patients with stable disease at Cipto Mangunkusumo hospital and Hasan Sadikin hospital during November 2015−March 2017 who met the selection criteria and continued to receive standard therapy. The subjects were randomly allocated into two groups: the study group received the ciplukan extract 3 x 250 mg / day for 12 weeks and the placebo group. Examination of MRSS, ESR, P1NP, BAFF and sCD40L was performed every 4 weeks until the end of the study. Results: fifty-nine subjects completed the study. They consisted of 29 subjects of the treatment group and 30 of the placebo group, with an average age of 41 (SD 9) years, the proportion of women: male = 9 : 1. There was a significant improvement of skin fibrosis in the study group with a highly significant decrease in MRSS (35.9% VS 6.3%, p <0.001) and a relative decrease in P1NP levels (17.8% VS 0.7%, p = 0.002). No decrease in ESR, BAFF and sCD40L levels in both groups. There was a weak but significant positive correlation between MRSS with P1NP levels (r = 0.236, p = 0.036). Conclusion: Ciplukan extract with dose 3 x 250 mg for 12 weeks as adjuvant on scleroderma standard therapy alleviates skin fibrosis significantly based on MRSS and P1NP levels."